 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients |
(Hospital Universitari de Bellvitge) (Centro de Investigación Biomédica en Red de Cáncer) (Centro de Investigación Biomédica en Red de Cáncer) (Institut d'Investigació Biomèdica Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) (Hospital Universitari de Bellvitge) (Hospital Universitari de Bellvitge) (Hospital Universitari de Bellvitge)| Data: | 2018 |
| Resum: | Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa,b 7th edition). Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p16. HPV16-E5 expression was found in 41 of 53 samples (77. 4%). EGFR expression was observed in 37. 7 vs 70. 8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0. 15) 5% CI = 0. 04-0. 56]). Expression of pEGFR followed an inverse pattern with 39. 6 and 24. 9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1. 58 [95% CI = 0. 48-5. 17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39. 36 months (min = 0. 03 - max = 272. 07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0. 001, for both) and DFS (p < 0. 001 for EGFR and p = 0. 003 for pEGFR). HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients. |
| Ajuts: | Ministerio de Ciencia e Innovación PI1102096 Ministerio de Economía y Competitividad PI1401918 Ministerio de Economía y Competitividad PI1500500 Ministerio de Economía y Competitividad PI1501205 Ministerio de Economía y Competitividad RD12/0036/0056 Ministerio de Economía y Competitividad CB16/12/00401 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | EGFR ; HPV ; HPV16 ; HPV16-E5 ; Human Papillomavirus ; Head and neck cancer ; Oropharyngeal cancer ; PEGFR |
| Publicat a: | Frontiers in Oncology, Vol. 8 Núm. DEC (2018) , p. 589, ISSN 2234-943X |
